Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  SBI Holdings Inc    8473   JP3436120004

SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

SBI Holdings, Inc. : Basic Agreement Reached with the Bahrain Development Bank for Promoting 5-ALA Business in Bahrain

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/21/2013 | 07:53am CET

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in

reliance upon the whole or any part of the contents of this announcement.

SBI HOLDINGS, INC.

(Incorporated in Japan with limited liability)

(Stock code: 6488) OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The
Stock Exchange of Hong Kong Limited.

Please refer to the attached copy of the Announcement.

On behalf of the Board SBI Holdings, Inc. Yoshitaka Kitao Representative Director,

President & Chief Executive Officer

Japan, 21 March 2013

As of the date of this announcement, the executive Directors are Mr Yoshitaka Kitao, Mr Taro Izuchi, Mr Takashi Nakagawa, Mr Tomoya Asakura, Mr Shumpei Morita, Mr Noriaki Maruyama and Mr Peilung Li, the non-executive Directors are Mr Hiroyoshi Kido, Mr Noriyoshi Kimura, Mr Hiroshi Tasaka and Mr Takashi Okita and the independent non-executive Directors are Mr Masaki Yoshida, Mr Kiyoshi Nagano, Mr Keiji Watanabe, Mr Akihiro Tamaki and Mr Masanao Marumono.

21 March 2013
SBI Holdings, Inc. (TOKYO: 8473 / Hong Kong: 6488)

Basic Agreement Reached with the Bahrain Development Bank for Promoting 5-ALA Business in Bahrain

We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo;
Representative Director and CEO: Yoshitaka Kitao; "SBI Pharmaceuticals"), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1), has reached a basic agreement to cooperate in promoting the 5-ALA business in Bahrain
with the Bahrain Development Bank (Location: Manama, Bahrain; Representative: Shaikh Mohammed Bin Essa Bin Mohammed Al Khalifa) that is engaged in providing business support to small- and medium-sized companies under the umbrella of the Bahrain government.
The Bahrain Development Bank is a governmental financial institution in Bahrain and was established in 1992 for promoting the business projects of small- and medium-sized companies in Bahrain.
SBI Pharmaceuticals is currently working with various partners, including local universities, research institutions and private companies, as it prepares for the research and development of pharmaceuticals which use 5-ALA and for manufacturing and selling 5-ALA related products; and it will promote the research and development as well as the manufacturing and sales of pharmaceuticals which use 5-ALA, while relying on local legal and financial advice and support from the Bahrain Development Bank. SBI Pharmaceuticals is hoping to further accelerate the expansion of its 5-ALA business in Bahrain, with the cooperation of the Bahrain Development Bank obtained by this basic agreement.
SBI Pharmaceuticals will continue to cooperate closely with the Bahrain government in promoting the business, while pursuing various possibilities of 5-ALA in order to contribute to the health of as many people in the
world as possible, and will make every effort to work on research and development as well as on spreading
5-ALA related products with partners both inside and outside Japan.

(*1) 5-aminolevulinic acid (5-ALA): An amino acid created in mitochondria. It is an important substance that serves as protein material related to energy production in the form of hemes and cytochromes, and its productivity is known to decrease with age. 5-ALA is contained in shochu distillation remnants, red wine and food such as radish sprouts. It is also known as a material forming chloroplasts in plants.

**************************************************************************************** For further information, please contact:
SBI Holdings, Inc.: Corporate Communications Dept., Tel: +81 3 6229 0126
SBI Pharmaceuticals Co., Ltd.: Corporate Planning Dept., Tel: +81 3 6229 0095

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SBI HOLDINGS INC
09/27 SBI HOLDINGS INC : ex-dividend day for interim dividend
09/22 SBI : Japan buys 20% stake in Wealth Trust Securities
09/21 SBI : Notice Regarding Share Acquisition of Wealth Trust Securities in Sri Lanka..
09/19 SBI : Notice Regarding Business Alliance in Virtual Currency Area with CoVenture..
08/30 SBI : Notice on Results of Repurchase of the Company's Own Shares through ToSTNe..
07/28 SBI : Partial Determination of Details of Issuance of Stock Acquisition Rights(P..
07/28 SBI : Issuance of Stock Acquisition Rights (Paid-In Capital Stock Options and Qu..
07/19 SBI : First Quarterly Results Announcement for the Three Months Ended June 30, 2..
06/23 SBI : FDA has Approved Intraoperative Imaging Agent for Malignant Glioma, One of..
06/08 SBI : Listing of Sihanoukville Autonomous Port in Cambodia with SBI Royal Securi..
More news
News from SeekingAlpha
11/09 THE BEST IS YET TO COME FOR BITCOIN : What To Do Now
10/27 SBI Holdings, Inc. 2017 Q2 - Results - Earnings Call Slides
Financials ( JPY)
Sales 2018 289 B
EBIT 2018 -
Net income 2018 34 863 M
Debt 2018 -
Yield 2018 3,28%
P/E ratio 2018 10,05
P/E ratio 2019 10,13
Capi. / Sales 2018 1,28x
Capi. / Sales 2019 1,21x
Capitalization 370 B
Chart SBI HOLDINGS INC
Duration : Period :
SBI Holdings Inc Technical Analysis Chart | 8473 | JP3436120004 | 4-Traders
Technical analysis trends SBI HOLDINGS INC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 1 650  JPY
Spread / Average Target 0,24%
EPS Revisions
Managers
NameTitle
Yoshitaka Kitao President & Representative Director
Tomoya Asakura Director & Senior Managing Executive Officer
Shumpei Morita Director & Managing Executive Officer
Masaki Yoshida Director
Takashi Nakagawa Representative Director & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
SBI HOLDINGS INC10.54%3 298
CITIC LTD0.72%41 647
MACQUARIE GROUP LTD12.95%25 478
NATIXIS21.88%24 160
CHINA HUARONG ASSET MANAGEMENT CO LTD31.18%18 311
INVESTEC-7.37%6 669